Andreas Kulozik

Prof. Dr. Andreas Kulozik is a Professor of Pediatrics and Hematology/Oncology at Heidelberg University, leading the Department of Pediatric Oncology, Hematology and Immunology at Heidelberg University Hospital. His work focuses on genetic and molecular mechanisms underlying pediatric hematologic malignancies and inherited blood disorders, with a particular emphasis on β-thalassemia, sickle cell disease, and T-cell acute lymphoblastic leukemia (T-ALL). He is a pioneer in gene therapy applications for transfusion-dependent anemias, including landmark studies on betibeglogene autotemcel (beti-cel) therapy for β-thalassemia.

Research Interests:

• Gene therapy for hemoglobinopathies
• Molecular profiling of pediatric leukemias
• Genetic counseling for cancer predisposition syndromes
• Long-term outcomes of stem cell-based therapies
• Novel therapeutic targets in osteosarcoma and T-ALL

Recent Article Trends: His 2023-2025 publications highlight advancements in beti-cel gene therapy efficacy, genomic profiling of T-ALL relapse mechanisms, and interdisciplinary approaches to managing genetic cancer risks. Ongoing work explores epigenetic drivers in leukemia and the functional impact of somatic mutations in sarcomas.

Clinical Contributions: Leads the German sickle cell disease registry and newborn screening initiatives, improving early detection and care for hemoglobinopathies. Collaborates internationally on precision oncology through platforms like the Pediatric Precision Oncology INFORM registry.